Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women
Open Access
Abstract
BACKGROUND In the Ashkenazim, three recurrent germline mutations have been identified in the breast carcinoma susceptibility genes BRCA1 and BRCA2: 185delAG, 5382insC (BRCA1), and 6174delT (BRCA2). The frequency of these mutations in the general Ashkenazi population approaches 2%. There is little available controlled data comparing the characteristics of breast carcinoma arising in BRCA1 mutation carriers or BRCA2 mutation carriers with that arising in noncarriers, although such data would be relevant to the urgent clinical need to develop risk‐reduction strategies for individuals at increased risk due to genetic factors. METHODS The authors screened 149 unselected tumors arising in Ashkenazi Jewish women for the 185delAG, 5382insC, and 6174delT mutations and compared tumors arising in mutation carriers with tumors arising in noncarriers with respect to nuclear grade, steroid hormone receptor status, and axillary lymph node status. RESULTS In the 149 cases, the authors found 17 BRCA1 mutations (11.4%; 95% confidence interval [ci], 6.8‐17.6%), and 4 6174delT BRCA2 mutations (2.7%; 95% CI, 0.8‐6.7%). Tumors from women with BRCA1 mutations were significantly less likely to be estrogen receptor positive (age‐adjusted odds ratio [or]: 0.091; P < 0.001) and more likely to have a high nuclear grade (OR: 5.55; P 0.001) than tumors in which no mutation was identified. All four BRCA2 positive breast carcinoma specimens were estrogen receptor positive. CONCLUSIONS Breast carcinoma arising in Ashkenazim BRCA1 mutation carriers has adverse prognostic features relative to those arising in noncarriers in the same population. This may be relevant to the development of prevention and treatment strategies for these women. For example, if tamoxifen reduces the risk of breast carcinoma via its antiestrogenic effects, it is possible that this effect will be diminished in the largely estrogen receptor negative BRCA1‐related hereditary breast carcinoma. Cancer 1997; 80:435‐41. © 1997 American Cancer Society.Keywords
This publication has 17 references indexed in Scilit:
- Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer familiesNature Medicine, 1996
- The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%Nature Genetics, 1996
- Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2Nature Genetics, 1996
- Germline BRCA1 185delAG mutations in Jewish women with breast cancerThe Lancet, 1996
- Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancerNature Genetics, 1996
- The complete BRCA2 gene and mutations in chromosome 13q-linked kindredsNature Genetics, 1996
- Germ-LineBRCA1Mutations in Jewish and Non-Jewish Women with Early-Onset Breast CancerNew England Journal of Medicine, 1996
- Identification of the breast cancer susceptibility gene BRCA2Nature, 1995
- The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individualsNature Genetics, 1995
- Frontometaphyseal dysplasia: Neonatal radiographic diagnosisAmerican Journal of Medical Genetics, 1995